Teva reported on their first quarter results and issued the following press release with the following headlines and statements from the CEO: – Revenues of $4.3 billion – GAAP diluted loss per share of $0.10 – Non-GAAP diluted EPS of $0.60 – Free cash flow of $360 million – Spend base reduction of $2.5 billion …
Tag Archives: Ajovy
Teva and the approval of the migraine drug Ajovy®
Teva announced the FDA approval of their migraine drug Ajovy® (Fremanezumab) – a mAB CGRP inhibitor – in a press release on September 21st. I felt it would be a good time to revisit Teva and migraine drugs, since a lot of things have happened, since their largest ever acquisition of Actavis Generics from Allergan …
Continue reading “Teva and the approval of the migraine drug Ajovy®”